// App-Quantinova.ai

PARE0009 : COMMUNITY ADVISORY BOARD INPUT CAN MAKE LAY SUMMARIES OF CLINICAL TRIAL RESULTS MORE UNDERSTANDABLE

Researchers

Presenter

  • J. Welling

Principal Investigators

  • A. Roennow

  • M. Sauv

  • E. Brown

  • I. Galetti

  • A. Gonzalez

  • A. P. Portales Guiraud

  • A. Kennedy

  • C. Leite

  • R. J. Riggs

  • A. Zheng

  • M. Perkovic Popovic

  • A. Gilbert

  • L. Moros

  • K. Sroka-Saidi

  • T. Schindler

  • H. Finnern

Medical Centers

  • Federation of European Scleroderma Associations aisbl. (FESCA), Saint Maur, Belgium

  • Sklerodermiforeningen, Rødovre, Denmark

  • Scleroderma Canada, Hamilton, Canada

  • Scleroderma and Raynaud’s UK, London, United Kingdom

  • Gruppo Italiano Lotta alla Sclerodermia (GILS), Milano, Italy

  • Scleroderma Research Foundation, San Francisco, United States of America

  • Asociación Española de Esclerodermia, Madrid, Spain

  • Associação Portuguesa de Doentes com Esclerodermia, Matosinhos, Portugal

  • Scleroderma Foundation, Danvers, United States

  • Chinese Organization for Scleroderma, Chengdu, China

  • Croatian Society for Patients with Scleroderma, Zagreb, Croatia

  • Boehringer Ingelheim International GmbH, Patient Advocacy Relations, Ingelheim am Rhein, Germany

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

Locations

  • Belgium

  • Denmark

  • Canada

  • United Kingdom

  • Italy

  • United States

  • Spain

  • Portugal

  • China

  • Croatia

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Scleroderma

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02597933

Sponsors

  • Boehringer Ingelheim and Janssen

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved